Higher lifestyle oxidative balance scores are associated with lower metabolic dysfunction-associated fatty liver disease and fibrosis risk in US adults, while dietary scores lack impact on fibrosis.

Keywords

liver fibrosis, Metabolic dysfunction associated steatotic liver disease, oxidative balance score, lifestyle oxidative balance score

Abstract

Introduction

Metabolic dysfunction related steatotic liver disease (MASLD) is a long-term liver disease.Oxidative stress plays a key role in MASLD. The oxidative balance score (OBS) measures oxidative and reactive stress, but its relationship with MASLD and fibrosis remains unclear.

Material and methods

The National Health and Nutrition Examination Survey records from 1999 to 2018 were used in this study. We used weighted multivariate logistic regression, subgroup studies, and limited cubic spline regression to look at the links between OBS and MASLD and fibrosis. Sensitivity studies were done to see how strong the results were.

Results

A total of 12,272 people enrolled in the study. There was a strong negative relationship between OBS and MASLD, and all p values for interactions were less than 0.05. After adjusting for potential confounders, people with higher OBS had a lower chance of MASLD (OR=0.37, 95%CI(0.27–0.51), p for trend <0.001). Then, the stratified studies showed that lifestyle OBS was significantly linked to MASLD in both men and women, but dietary OBS was only significantly linked to MASLD in men (OR=0.95, 95%CI(0.93, 0.98), p<0.001). Finally, lifestyle OBS showed a strong association with MASLD-related fibrosis (OR = 0.37, 95%CI (0.24, 0.56), p for trend < 0.0001). In the subgroup studies, the findings stayed consistent.

Conclusions

OBS was linked to a lower chance of MASLD, and lifestyle OBS showed strong protective effects against MASLD and fibrosis. Because of this, people who have MASLD and fibrosis should focus on researching and looking into antioxidant treatment that is based on dietary and lifestyle, with particular emphasis on lifestyle factors.

1 Higher lifestyle oxidative balance scores are associated with lower

2 metabolic dysfunction-associated fatty liver disease and fibrosis risk

3 in US adults, while dietary scores lack impact on fibrosis.

4

5 Abstract

Background:Metabolic dysfunction related steatotic liver disease (MASLD) is a
long-term liver disease. Oxidative stress plays a key role in MASLD. The oxidative
balance score (OBS) measures oxidative and reactive stress, but its relationship with
MASLD and fibrosis remains unclear.

Methods: The National Health and Nutrition Examination Survey records from 1999 to 2018 were used in this study. We used weighted multivariate logistic regression, subgroup studies, and restricted cubic spline regression to look at the links between OBS and MASLD and fibrosis. Sensitivity studies were done to see how strong the results were.

Results: A total of 12,272 people enrolled in the study. There was a strong negative 15 relationship between OBS and MASLD, and all p values for interactions were less 16 17 than 0.05. After adjusting for potential confounders, people with higher OBS had a lower chance of MASLD (OR=0.37, 95%CI(0.27-0.51), p for trend <0.001). Then, the 18 19 stratified studies showed that lifestyle OBS was significantly linked to MASLD in both men and women, but dietary OBS was only significantly linked to MASLD in 20 21 men (OR=0.95, 95%CI(0.93, 0.98), p<0.001). Finally, lifestyle OBS showed a strong association with MASLD-related fibrosis (OR = 0.37, 95%CI (0.24, 0.56), p for trend 22 23 < 0.0001). In the subgroup studies, the findings stayed consistent Conclusion: OBS was linked to a lower chance of MASLD, and lifestyle OBS 24

24 Conclusion: OBS was linked to a lower chance of MASLD, and lifestyle OBS 25 showed strong protective effects against MASLD and fibrosis. Because of this, people 26 who have MASLD and fibrosis should focus on researching and looking into 27 antioxidant treatment that is based on dietary and lifestyle, with particular emphasis 28 on lifestyle factors.

29

Keywords: Metabolic dysfunction associated steatotic liver disease; liver fibrosis;
 oxidative balance score; lifestyle oxidative balance score

32

1

2 **1.Introduction**

3 Nonalcoholic fatty liver disease (NAFLD), a prevalent chronic liver condition characterized by abnormal fat buildup in the liver, is closely associated with metabolic 4 syndrome [1]. The prevalence of NAFLD is continuously on the rise, with around 25% 5 of the global population currently affected [2]. As a result, NAFLD has become a 6 7 significant public health concern [3-4]. In 2020, it was suggested that the name and description of NAFLD should be changed to metabolic dysfunction related steatotic 8 liver disease (MASLD) and that at least one of five cardiometabolic risk factors 9 should be present. This would better reflect the cause of the disease. The term 10 11 "steatotic liver disease" (SLD) was kept to include all the different causes of steatosis, such as MASLD, MetaALD (people with MASLD who drink more alcohol), Other 12 specific aetiology SLD (like alcoholic liver disease(ALD), drug-induced liver 13 injury(DILD), and monogenic diseases), and cryptogenic SLD (with no metabolic 14 15 parameters and no known cause)[5]. Oxidative stress (OS) plays a significant role in MASLD as indicated by a recent study[6]. It is characterized by an imbalance 16 between pro-oxidants and antioxidants,, which leads to more reactive oxygen species 17 (ROS) in redox processes. ROS can damage lipids, proteins, and DNA through 18 oxidative damage[7-8]. Prior research has shown that getting more of certain nutrients, 19 like calcium, vitamin E,D and C, zinc, magnesium, and selenium, makes you less 20 likely to get oxidative stress (OS). In contrast, bad habits like smoking and drinking 21 too much alcohol increase the production of reactive oxygen and nitrogen species 22 23 (RONS), which speeds up the cell harm linked to OS[9-11]. However, because pro-oxidants and antioxidants work with each other in a complicated way, a single 24 OS-related factor has a small impact on the oxidative/antioxidant system. The 25 oxidative balance score (OBS) was created to measure a person's oxidative and 26 antioxidant state. It has two parts: the dietary OBS and the lifestyle OBS[12]. 27

OBS is negatively associated with a variety of diseases, such as metabolic syndrome, hypertension, chronic kidney disease, and so on. However, few observational studies have investigated the association of OBS risk with MASLD and
fibrosis. The study hypothesizes that OBS, including dietary OBS and lifestyle OBS,
are negatively correlated with MASLD and MASLD-related fibrosis. Using data from
the National Health and Nutrition Examination Survey (NHANES), this study goes on
to find that a different result is more likely.

6 2.Materials and methods

7 2.1 Study population

8 This cross-sectional study included subjects from the nationally representative 9 consecutive NHANES 1999 - 2018. To ensure a representative sample, we

consolidated sociodemographic information, personal life history, dietary records, and 10 laboratory data from ten cycles of the NHANES. Of the 59204 subjects who aged 20 11 years or older in the NHANES 1999-2018, individuals were excluded if (1) missing 12 data on the US fatty liver index (US FLI), Fibrosis-4 Index (FIB-4) or NAFLD 13 fibrosis score(NSF) (n=35029); (2) with a history of excessive alcohol consumption 14 15 (>2 drinks/day and >3 drinks/day for women and men respectively) (n=2259);(3)and exhibiteding any indication of other causes of chronic liver disease such as MetALD, 16 viral hepatitis infection, autoimmune hepatitis, liver cancer or cryptogenic SLD (n 17 =2977); (4) less than 16 items for a total of 20 components of the OBS (n =18 19 939);(5)missing data on several covariates and weighting(n =4588);(6) we further excluded 499 participants with pregnant, and 641 participants who had missing diet 20 data or extreme diet data (total energy intake of <800 or >4200 kcal day- 1 for males 21 and <500 or >3500 kcal day- 1 for females). The percentage of missing data for each 22 23 covariate was less than 5%, so missing values were not imputed. Ultimately, a total of

24 12272 subjects were enrolled in this research (Fig. 1).

The National Centre for Health Statistics' Ethical Review Committee approved NHANES, and all participants provided written informed consent. This research adhered to the applicable guidelines and regulations (https://www.cdc.gov/nchs/data_access/restrictions.htm).

29 **2.2. MASLD and liver fibrosis assessment**

3

The US fatty liver index (USFLI) was used to define MASLD in this study and was
derived specifically for the NHANES database, with a cut-off of 30 to define MASLD
[13].In addition, we calculated the Fibrosis-4 (FIB-4) score and MASLD fibrosis
score(NSF) to assess liver fibrosis, and participants with FIB-4 scores≥2.67 or NFS >
0.676 were considered to have liver fibrosis[14]. The formulas of USFLI and FIB-4
can be found in Supplementary Table 3.

7 2.3. Oxidative balance score

The OBS was made by adding up the numbers for each of the four lifestyle factors 8 and the 16 nutrients, which include 5 pro-oxidants and 15 antioxidants. We found out 9 how much of 16 nutrients people ate, such as fiber, total fat, carotene, riboflavin, 10 niacin, calcium, zinc, magnesium, copper, selenium, iron, total folate, vitamins B12, 11 C, and E, by asking people to remember what they ate for 24 hours. The estimate did 12 not take into account dietary supplements or medicine sources. Physical exercise, 13 body mass index (BMI), alcohol use, and smoking (nicotine amounts) were all 14 15 lifestyle-based OBS factors [9]. Total fat, iron, drinking booze, smoking, and BMI were all thought to be pro-oxidants. Three groups were made up of people who drank 16 alcohol: heavy drinkers (15 g/d for women and 30 g/d for men), light drinkers (0 to 15 17 g/d for women and 0 to 30 g/d for men), and nondrinkers. The questions in this 18 section covered lifetime and recent (past 12 months) use of alcohol for ages 20 years 19 and over. Each group was given a score between 0 and 1, and the nondrinkers got a 20 score of 2 [9]. Then, the other parts were split into three groups based on their tertile. 21 Antioxidants were assigned a score on a scale from 0 to 2, with the lowest tertile 22 (tertile 1) receiving 0 points, the middle tertile (tertile 2) receiving 1 point, and the 23 24 highest tertile (tertile 3) receiving 2 points. In contrast, the scoring for prooxidants was structured in an inverse manner. The highest tertile, which represents the greatest 25 concentration or presence of prooxidants, was assigned 0 points, and the lowest tertile 26 was given 2 points, reflecting the higher score for lower levels of prooxidants[9]. The 27 groups were then split into two groups based on sex. The protective effect is stronger 28 when the OBS score is higher. 29

1 2.4. Covariates

In our study, we have selected several variables previously displayed or may 2 influence MASLD or OBS and collected the following information : age, sex, race 3 (Mexican American, Other Hispanic, Non-Hispanic black, Non-Hispanic white, Other 4 race including multiracial), education, marital status (having partner, no partner, 5 unmarried), and poverty-to-income ratio (PIR) (<1.3, 1.3 to 3.5, >3.5), fasting glucose, 6 7 fasting insulin, glycated hemoglobin, homeostasis model assessment insulin resistance (HOMAIR,=fasting glucose (mmol/L) * fasting insulin (mU/mL)/22.5), total 8 cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL) and low-density 9 lipoprotein (LDL), C-reactive protein (CRP), alanine aminotransferase, aspartate 10 11 aminotransferase, gamma-glutamyl transferase, the 2015 version of the Healthy Eating Index (HEI) and total energy intake, hypertension, diabetes, and cardiovascular 12 disease. 13

14 **2.5. Statistical analysis**

The scoring for this study was based on guidance from the Centers for Disease 15 Control and Prevention (CDC). The data came from forms 1999–2000 and 2001–2002, 16 so the formula was 2/5* WTDR4YR(Dietary day one 4-Year sample weight) or 3/5* 17 WTDRD1(Dietary day one 2-Year sample weight) to take into account the 18 NHANES's complex multistage cluster survey design.During data handling and 19 analysis, we made sure that continuous variables had a normal distribution. For 20 variables with a normal distribution, we used the weighted mean \pm standard error (SE), 21 and for variables with a nonnormal distribution, we used the interquartile range 22 23 (IQR).Next, the weighted one-way ANOVA or Kruskal-Wallis's H tests were used to look at continuous variables. The weighted chi-square tests were used to look at 24 categorical variables, which were given as numbers (weighted percentages). It was 25 broken up into quartiles, with Q1 being the lowest (13–13), Q2 being the next lowest 26 (13-19), Q3 being the next lowest (19-25), and Q4 being the highest (25-37).We 27 looked at the link between different OBS and MASLD and MASLD-related fibrosis 28 using weighted logistic regression models. The OBS were broken down into two 29

groups: dietary OBS and lifestyle OBS. In the unadjusted model, no factors were 1 modified, while Model 1 was adjusted for age, sex, race, marital status, education, PIR, 2 smoking status and alcohol intake. To assess trends, the median value of each variable 3 was also used. Moreover, Model 2 included additional adjustments for SII and total 4 energy intake (kcal), while Model 3 was further adjusted for ALT, ASST, GGT, Scr, 5 BUN, total energy, TC, glucose, TG, DM, CVD, hypertension and stroke.Subgroup 6 analyses were also done based on race, gender, age, family income to poverty ratio, 7 amount of schooling, and marriage status. Once all of Model 3's factors had been 8 changed, restricted cubic splines (RCS) were used to look at nonlinear relationships 9 and show general trends between the different OBS and MASLD. Also, to test how 10 stable the data were, sensitivity studies were done by taking out one part of the overall 11 OBS at a time. A two-tailed p number less than 0.05 was thought to be statistically 12 significant. R version 4.3.1 was used for all statistics studies 13 (http:// www.R-project.org). 14

15 **3. Results**

3.1. Baseline characteristics

A total of 12,272 individuals participated in this study. Of these, 3,480 had MASLD, comprising 28.35% of the study sample.In Table 1, the baseline features of the subjects are shown, grouped by OBS quartiles.In the study, the average age of the people who took part was 50.34 ± 0.29 years, and 72.47% of them were non-Hispanic white.

People in the top quartile of OBS were younger and more likely to be Non-Hispanic White (78.04%) than people in the bottom quartile of OBS.People in the highest OBS quartile were wealthier, had more schooling, ate more, had higher HEI, higher HDL, lower CRP, lower GGT, lower LDH, lower CRP, lower HOMA IR, and were more likely to have partners than people in the lowest OBS quartile. The sex difference between the OBS groups was not important from a statistical point of view. As OBS went up, the number of people with MASLD and its associated diseases, such as diabetes, high blood pressure, heart disease, stroke, and fibrosis caused by MASLD,
 slowly went down.

3 3.2. Association between different OBS and MASLD and 4 MASLDrelated fibrosis

Table 2 shows the relationships between different OBS and MASLD, as well as 5 MASLD related fibrosis. This study using weighted logistic regression analysis 6 7 discovered a significant negative association between various OBS and MASLD. First, in Model 3 with all the changes made, the highest quartile of OBS 8 (OR=0.37(0.27,0.51), p < 0.001) was more strongly linked to a lower risk of MASLD 9 than the lowest quartile of OBS (OR=0.77(0.62,0.97), p=0.03). Second, the risk of 10 11 MASLD went down with higher lifestyle OBS (OR=0.14(0.10-0.19), p< 0.0001).Lastly, having more dietary OBS was linked to a lower chance of MASLD 12 (OR=0.48(0.36,0.66), p < 0.0001). Statistically, the falling trend was important (p < 13 0.05 for all trends), as shown by the trend test. While both the OBS and lifestyle 14 15 OBS were negatively associated with fibrosis, no significant link was found between fibrosis and dietary OBS in MASLD patients (OR = 0.72(0.48, 1.08), p = 0.08). 16

17 **3.3.Stratification and sensitivity analyses**

We conducted stratification analyses to assess the robustness of the association 18 between different OBS and MASLD and related fibrosis(Fig.2 and Supplementary 19 Table 2A-B). When stratified by age and sex, the results showed that OBS was 20 negatively associated with the prevalence of MASLD in all levels, but there was no 21 inconclusive association between OBS and MASLD related fibrosis. Additionally, 22 23 dietary OBS showed a significant negative association with MASLD, especially in men. When we separated the results by family income to poverty ratio (PIR) and 24 education level, we saw that both OBS and dietary OBS were significantly linked to 25 MASLD in people whose PIR was higher than 3.5 (OR=0.95(0.93,0.97)), or more 26 (OR=0.93(0.92,0.95)), 27 than high school or more than high school (OR=0.96(0.94,0.98)).On top of that, we discovered that the lifestyle OBS was 28 strongly linked to MASLD and fibrosis at all stages. We did sensitivity studies by 29

taking out each OBS component one at a time, and the MASLD values stayed the
same (Supplemental Table 1). But when body mass index, physical exercise, copper,
magnesium, and vitamin C were taken out, the results for MASLD-related fibrosis
were not clear and could not be interpreted in a useful way. We also found that eating
OBS and lifestyle OBS did not affect each other in the whole group (p for
interaction=0.677).

7 3.4. Analysis of restricted cubic spline regression

We found a nonlinear relationship between OBS and MASLD in restricted cubic 8 spline regression (RCS) (Figure.3; p for nonlinear =0.0001; Figure.3A). We also 9 found a significant nonlinear relationship in women and people aged 20 to 60 (p for 10 11 nonlinear =0.0012; p for nonlinear =0.0001; Figure.3B and 3C). This picture (Fig. 2A, 2B, and 2C) shows that the risk of MASLD went down as OBS went up. This trend 12 was seen in both men and patients aged 60 and up.Lifestyle OBS was linked to a 13 lower risk of MASLD in a way that wasn't linear (p for nonlinear < 0.0001, 14 Figure.3D), and this link stayed the same for both male and female subgroups and all 15 age groups (p for nonlinear < 0.0001, Figure.3E and 3F). There was a negative linear 16 relationship between dietary OBS and the chances of MASLD (P for nonlinear = 17 0.2923; Fig. 3H). There was also a negative linear relationship between dietary OBS 18 and MASLD in different age or gender groups and in patients aged 60 or more (Fig. 19 3I and 3J). The nonlinear analysis of the RCS gave slightly different results, but the 20 overall trends of the dependent and independent factors were generally negative. 21

22 **4.Discussion**

We did a cross-sectional study of 12272 people in the NHANES dataset to find out more about the link between OBS and MASLD.We saw that total OBS and lifestyle OBS were both linked to a lower chance of MASLD and fibrosis. This supports the idea that OBS has a major effect on the development and worsening of MASLD, and the link was the same for both men and women.Our research also discovered that having higher OBS and lifestyle OBS scores is not always linked to a lower chance of MASLD.Our research showed that dietary OBS were negatively

linked to the number of cases of MASLD but not to fibrosis related to MASLD. Also, 1 dietary OBS were only negatively linked to MASLD in men.A previous study showed 2 that women may have a better antioxidant capacity than men. This could be because 3 estrogen has antioxidative effects and antioxidant enzyme activity varies between men 4 and women [15,16]. It's not clear what exactly causes these differences between men 5 and women, but they may have something to do with oxidative stress and the biology 6 of MASLD [17]. Dietary habits and quality of life are both important factors that 7 affect MASLD, but they may have a bigger effect on men. 8

9 Several oxidative stress biomarkers, including malondialdehyde and nitric oxide, were found to be higher in the serum of people with MASLD compared to controls. 10 At the same time, concentrations of several antioxidant biomarkers, including 11 glutathione, glutathione peroxidase, and super oxide dismutase, were significantly 12 lower [18,19]. In the pathophysiology of MASLD/NASH, hepatic lipotoxicity leads to 13 failure in several ROS-producing cell compartments. This causes too much 14 production and release of ROS, which throws off the balance of redox signals. Also, 15 16 more and more clinical evidence suggests that adding a variety of antioxidants to a person's diet, such as beta-carotene, vitamins A, E, and C, along with making lifestyle 17 changes like doing aerobic exercise, may help improve some clinical indicators by 18 lowering oxidative stress in MASLD/NASH patients[20,22]. Since there aren't many 19 accepted drug treatments for MASLD, changes to dietary and lifestyle are still the 20 most important things that people can do to help.[23]. The OBS is very useful because 21 22 it can be used to check a person's general redox balance. A lot of different study groups have looked into how it might be linked to different metabolic illnesses or 23 24 conditions. For example, studies have shown that a higher OBS is linked to a lower chance of having new-onset hypertension and metabolic syndrome. It is also linked to 25 better control of blood sugar, especially in adults with type 2 diabetes.[24-26]. The aim 26 of this study was to find out how OBS, which shows the balance of pro-oxidants and 27 antioxidants, is related to the number of cases of MASLD. As with other studies [27], 28 OBS in ours has parts that have been studied before, like dietary fiber, total fat, 29 carotene, riboflavin, niacin, calcium, zinc, magnesium, copper, selenium, iron, total 30

folate, vitamins B12, C, and E, as well as information about smoking, physical activity, body mass index (BMI), and total folate.Even when all the other factors that were looked at were taken into account, OBS was still linked to the chance of MASLD and fibrosis. In the Q4 population, the chance of MASLD and fibrosis was 63% and 40% lower than in the Q1 population with OBS (p trend<0.0001).</p>

Higher lifestyle OBS and dietary OBS were each independently linked to a lower 6 risk of MASLD, showing reductions of around 86% and 52% in the population with 7 OBS in the Q4 quartile compared to Q1, respectively. Notably, the chance of fibrosis 8 was 63% lower in Q4 compared to the group with lifestyle OBS in Q1. However, 9 dietary OBS was not linked to fibrosis in people with MASLD.So, lifestyle OBS 10 seems to be linked to a lower chance of MASLD and fibrosis more than dietary OBS. 11 The results of this study agree with those of a recent study using NHANES III[28], 12 which found that dietary factors are less important than physical exercise for the 13 outcome of people with MASLD. The basic processes are still not clear, so they need 14 to be looked into more in future studies. 15

To learn more about the complex connection between different OBS and the risk of MASLD, we used restricted cubic splines . The links between OBS and lifestyle OBS and MASLD risk were not linear (p for nonlinearity <0.0001). For OBS, the turning point was 19 points, and for lifestyle OBS, it was 5 points. After achieving 19 and 5 points, respectively, threshold effect analysis showed that OBS and lifestyle OBS were tied to a significant drop in MASLD risk. The way MASLD patients are treated might change because of these results.

Stratified analysis showed that all p-values for interaction were greater than 0.05 across different subgroups, hence indicating that the link between OBS and risk of MASLD was consistent regardless of individual characteristics. These results also suggest that OBS, particularly lifestyle OBS, may reduce MASLD risk across diverse populations. It's interesting that the P value for interaction was less than 0.05 for age groups when we looked into how lifestyle OBS affected the risk of fibrosis in those groups.After that, we looked for interactions and found that lifestyle OBS was more

10

strongly linked to the risk of fibrosis in people aged 41 or older, who were most likely
to benefit from a diet and lifestyle high in antioxidants (OR=0.8(0.7, 0.9)P<0.001).

Also, tests that took away each OBS component one at a time showed that the 3 results of MASLD stayed the same. The factors that had the biggest effect on 4 preventing fibrosis were vitamin C, magnesium, copper, physical exercise, and BMI. 5 A new study from NHANES found a strong link between higher serum copper 6 levels and a higher chance of both starting and getting worse MASLD and other 7 metabolic disorders[29]. A study in the U.S. population found a strong link between 8 blood vitamin C levels and better scarring in people with MASLD [30,31].A lot of 9 research has shown that exercise can help lower NASH and liver fibrosis by stopping 10 fat from building up in the liver[32,33]. The clinical guidelines also say that people 11 with MASLD should eat well and exercise to lose weight [34]. 12

This study has a lot of good points. In the first place, the OBS as a whole gives a 13 more complete picture of a person's total pro-oxidant and antioxidant intake. Second, 14 the NHANES data was chosen using a complicated multi-stage chance sampling 15 16 method, and it shows the general population of the US. Third, many other factors were taken into account in this study to greatly lessen the impact of factors that could 17 have caused confusion. Fourth, sensitivity and stratified studies showed that our 18 results were stable, and limited cubic spline regression helped us understand the 19 relationships better. 20

However, our work has some limitations as well. In the first place, it might be 21 22 hard to find a cause-and-effect link since the study was cross-sectional. This needs to 23 be shown in future studies through large-scale prospective cohort studies and randomized controlled trials. Second, since the study only looked at people in the US, 24 more research is needed to see if the results can be applied to people in other countries. 25 Third, one big problem with this study is that it doesn't use liver biopsies to diagnose 26 MASLD and fibrosis. Instead, it uses non-invasive markers, which could make the 27 results less accurate. But liver biopsy is expensive, can have problems, and can't be 28 used in large population-based studies. Non-invasive methods, on the other hand, are 29 a good alternative that has been shown to be accurate [35]. Diagnosis using 30

non-invasive scores is well understood, and these effects probably won't change how 1 reliable the results are. Additionally,, dietary OBS scores were calculated using a 2 24-hour dietary memory interview, which could have been skewed by remember bias. 3 We also used two 24-hour dietary records to do sensitivity analyses, but the results of 4 all the analyses in this study stayed pretty much the same. In the end, the dietary 5 6 culture in the U.S. differs greatly from other countries, with fast food, processed foods, and high sugar and fat intake being common. In contrast, many other countries (e.g., 7 Mediterranean and Asian nations) emphasize fresh foods, vegetables, and fruits. 8 9 While the U.S. has abundant food supply in supermarkets and fast food chains, other countries may rely more on seasonal or self-sustaining diets. These differences could 10 lead to inaccurate conclusions when using NHANES data for international 11 comparisons. 12

13 Conclusion

It was concluded that OBS was linked to a lower chance of MASLD. Notably, both dietary and lifestyle OBS helped lower the risk of MASLD incidence, both on their own and together. Also, the higher lifestyle OBS was better than the dietary OBS at lowering the number of cases of MASLD-related fibrosis. Lifestyle OBS showed strong protective benefits for MASLD and fibrosis linked to MASLD. Our results show that following an antioxidant-rich lifestyle and dietary is a good way to stop MASLD from happening.

- 21 **Consent for publication**
- 22 Not applicable.
- 23 Availability of data and materials
- All the data generated or analyzed during this study are available from the NHANES.
- 25 Funding

26 No Funding.

27 Authors' contributions

JF is responsible for making sure that the whole study is honest; YC is in charge of planning the study, doing the statistics, writing the paper, and correcting it. NC is in 1 charge of planning the study, defining the intellectual content, analyzing the data, and

2 reviewing the paper. YWC is in charge of researching the books and gathering data.

3 Acknowledgements

We sincerely appreciate the NHANES participants and staff for providing the data used in this study. Special thanks to Jing Zhang from the Second Department of Infectious Disease at Shanghai Fifth People's Hospital, Fudan University, for developing the nhanesR package and webpage, which have significantly facilitated access to the NHANES database.

9 Ethics approval and consent to participate

10 No one has to pay to get any information from the NHANES service, without raw data

11 collection, so ethics committee approval is not necessary. All data sources included in

12 this study complied with local laws and all participants signed informed consent.

13 **References**

- Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonal- coholic fatty liver disease: a
 feature of the metabolic syndrome. Diabetes 2001;50:1844–50.
- 16 2. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013;10:686–90.
- 17 3.Younossi ZM. Non-alcoholic fatty liver disease A global public health perspective. J Hepatol 2019;70:531–544.
- 18 4. Mitrovic B, Gluvic ZM, Obradovic M, Radunovic M, Rizzo M, Banach M, et al. Non-alcoholic fatty liver disease,
- metabolic syndrome, and type 2 diabetes mellitus: where do we stand today? Arch Med Sci. 2022 Jun
 3;19(4):884-894.
- 5. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multi- 301 society Delphi
 consensus statement on new fatty liver disease nomenclature. Hepatology 2023;302.
- 23 6.Fromenty B, Roden M. Mitochondrial alterations in fatty liver diseases. J Hepatol 2023;78:415e29.
- 24 7.Karnia M, Myslinska D, Dzik K, Flis D, Ciepielewski Z, Podlacha M et al. The Electrical Stimulation of the Bed
- Nucleus of the Stria Terminalis Causes Oxidative Stress in Skeletal Muscle of Rats. Oxid Med Cell Longev.
 2018;2018;4671213.
- 27 8.Yarana C, Carroll D, Chen J, Chaiswing L, Zhao Y, Noel T, et al .Extracellular vesicles released by
- 28 cardiomyocytes in a doxorubicin-induced cardiac injury mouse model contain protein biomarkers of early cardiac
- **29** injury. Clin Cancer Res 2018; 24:1644–1653.
- 30 9.Zhang W, Peng SF, Chen L, Chen HM, Cheng XE, Tang YH. Association between the oxidative balance score and
- telomere length from the national health and nutrition examination survey 1999-2002. Oxid Med Cell Longev
 2022;2022:1345071.
- 33 10. Barreiro E, Peinado V, Galdiz J, Ferrer E, Marin-Corral J, Sánchez F, et al. Cigarette smoke-induced oxidative
- stress: a role in chronic obstructive pulmonary disease skeletal muscle dysfunction. Am J Respir Crit Care Med
 2010;182:477–488.
- 36 11.Albano E. Alcohol, oxidative stress and free radical damage. Proc Nutr Soc 2006;65:278–290.

- 1 12.Hernández-Ruiz Á, García-Villanova B, Guerra-Hernández E, Carrión-García C, Amiano P, Sánchez M, et al.
- 2 Oxidative balance scores (OBSs) integrating nutrient, food and lifestyle dimensions: development of the
- 3 nutrientL-OBS and foodl-OBS. Antioxidants 2022; 11:300.
- 4 13.Ruhl CE, Everhart JE. Fatty liver indices in the multiethnic United States national health and nutrition
 5 examination survey. Aliment Pharmacol Ther 2015;41:65e76.
- 6 14.. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ, et al. Comparison of noninvasive markers
- 7 of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009;7:1104e12.
- 8 15.Kander MC, Cui Y, Liu Z. Gender difference in oxidative stress: a new look at the mechanisms for cardiovascular
- 9 diseases. J Cell Mol Med 2017;21:1024e32.
- 10 16. Zhang W, Peng SF, Chen L, Chen HM, Cheng XE, Tang YH. Association between the oxidative Balance
- score and telomere length from the national health and nutrition examination survey 1999-2002. Oxid Med Cell
 Longev 2022;2022:1345071.
- 13 17. Burra P, Bizzaro D, Gonta A, Shalaby S, Gambato M, Morelli MC, et al. Clinical impact of sexual dimorphism in
- 14 non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Liver Int 2021;41:1713e33.
- 15 18. Kumar A, Sharma A, Duseja A, Das A, Dhiman RK, Chawla YK, et al. Patients with nonalcoholic fatty liver
- disease (NAFLD) have higher oxidative stress in comparison to chronic viral hepatitis. J Clin Exp Hepatol
 2013;3:12e8.
- 18 19.Leghi GE, Domenici FA, Vannucchi H. Influence of oxidative stress and obesity in patients with nonalcoholic
 19 steatohepatitis. Arq Gastroenterol 2015;52:228e33.
- 20 20. Rives C, Fougerat A, Ellero-Simatos S, Loiseau N, Guillou H, Gamet-Payrastre L, et al. Oxidative stress in
- 21 NAFLD: role of nutrients and food contaminants. Biomol Ther 2020;10:21702.
- 22 21.Cheraghpour M, Imani H, Ommi S, Alavian SM, Karimi-Shahrbabak E, Hedayati M, et al. Hesperidin improves
- 23 hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty
- 24 liver disease: a randomized, placebo-controlled, double-blind clinical trial. Phytother Res 2019; 33:2118–25.
- 25 22.Farzanegi P, Dana A, Ebrahimpoor Z, Asadi M, Azarbayjani MA. Mechanisms of beneficial effects of exercise
- training on non-alcoholic fatty liver disease (NAFLD): roles of oxidative stress and inflammation. Eur J Sport Sci
 2019;19:994–1003.
- 23.Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J
 Hepatol 2017;67:829–46.
- 30 24.Noruzi Z, Jayedi A, Farazi M, Asgari E, Dehghani Firouzabadi F, Akbarzadeh Z, et al. Association of oxidative
- balance score with the metabolic syndrome in a sample of Iranian adults. Oxid Med Cell Longev2021;2021:5593919.
- 33 25.Lee JH, Son DH, Kwon YJ. Association between oxidative balance score and new-onset hypertension in adults: a
- 34 community-based prospective cohort study. Front Nutr 2022;9:1066159.
- 26.Golmohammadi M, Ayremlou P, Zarrin R. Higher oxidative balance score is associated with better glycemic
 control among Iranian adults with type-2 diabetes. Int J Vitam Nutr Res 2021;91:31e9.
- 37 27.Hernandez-Ruiz A, Garcia-Villanova B, Guerra-Hernandez E, Amiano P, RuizCanela M, Molina-Montes E. A
- review of A priori defined oxidative balance scores relative to their components and impact on health outcomes.
- **39** Nutrients 2019;11(4).
- 40 28.Yi Y, Wang C, Ding Y, He J, Lv Y, Chang Y. Diet was less significant than physical activity in the prognosis of
- 41 people with sarcopenia and metabolic dysfunction-associated fatty liver diseases: analysis of the National Health and
- 42 nutrition examination survey III. Front Endocrinol. 2023;14:1101892.

- 1 29.Li L, Yi Y, Shu X, Li J, Kang H, Chang Y. The Correlation Between Serum Copper and Non-alcoholic Fatty
- 2 Liver Disease in American Adults: an Analysis Based on NHANES 2011 to 2016. Biol Trace Elem Res. Published
- 3 online January 2024; 3.https://doi.org/10.1007/s12011-023-04029-9.
- 4 30.Liu X, Shen H, Chen M, Shao J. Clinical relevance of vitamins and carotenoids with liver steatosis and fibrosis
- 5 detected by transient elastography in adults. Front Nutr 2021; 8:760985.
- 6 31.Kim D, Konyn P, Cholankeril G, Ahmed A. Physical activity is associated with nonalcoholic fatty liver disease
- 7 and significant fibrosis measured by FibroScan. Clin Gastroenterol Hepatol 2022;20:e1438.
- 8 32.Chen G, Banini B, Do A, Lim JK. The independent effect of exercise on biopsy-proven non-alcoholic fatty liver
- 9 disease: a systematic review. Clin Mol Hepatol 2023;29:S319e32.
- 10 33.Houttu V, Bouts J, Vali Y, Daams J, Grefhorst A, Nieuwdorp M, et al. Does aerobic exercise reduce NASH and
- 11 liver fibrosis in patients with non-alcoholic fatty liver disease? A systematic literature review and meta-analysis.
- **12** Front Endocrinol 2022;13:1032164.
- 13 34.Wang M, Ma LJ, Yang Y, Xiao Z, Wan JB. n-3 Polyunsaturated fatty acids for the management of alcoholic liver
- disease: a critical review. Crit Rev Food Sci Nutr 2019;59:S116e29.
- 15 35.Ruhl CE, Everhart JE. Fatty liver indices in the multiethnic United States National Health and Nutrition
- 16 Examination Survey. Aliment Pharmacol Ther 2015;41:65–76.

participants extracted form NHANES1999-2018(age≥20 years) (n=59,204)

Exclusion:

missing data on USFLI $\$ FIB-4 and NFS(n=35029) with a history of excessive alcohol consumption(n=2259) exhibiteding any indication of other causes of chronic liver disease (n =2977) less than 16 items for a total of 20 components of the OBS (n = 939) missing data on several covariates and weighting(n =4588) participants with pregnant(n=499) missing diet data or extreme diet data(n=641)

Analyzed samples (n=12,272)

Variable	total	Q1	Q2	Q3	Q4	Pvalue
Age	50.34±0.29	50.68±0.47	51.41±0.52	49.85±0.49	49.57±0.53	0.03
Sex n(%)						0.06
Female	6468(53.38)	1592(54.95)	1656(50.88)	1728(52.68)	1492(55.30)	
Male	5804(46.62)	1503(45.05)	1569(49.12)	1547(47.32)	1185(44.70)	
Race n(%)						< 0.0001
Mexican American	1807(5.96)	429(5.96)	509(6.37)	477(5.78)	392(5.76)	
Other Hispanic	894(4.24)	207(4.40)	237(4.75)	246(3.96)	204(3.95)	
Non-Hispanic Black	2440(10.19)	910(17.59)	680(11.86)	534(7.87)	316(5.23)	
Non-Hispanic White	6042(72.47)	1350(64.73)	1537(70.80)	1676(74.47)	1479(78.04)	
Other Race - Including						
Multi-Racial	1092(7.13)	199(7.28)	263(6.21)	344(7.92)	286(7.01)	
Marital status n(%)						< 0.0001
Having a partner	7807(66.70)	1818(60.72)	2043(64.91)	2143(67.99)	1803(71.77)	
No partner	2741(18.82)	808(22.74)	734(20.50)	701(18.42)	498(14.53)	
Unmarried	1724(14.48)	469(16.54)	448(14.59)	431(13.59)	376(13.71)	
Ratio of family income to poverty r	n(%)					< 0.0001
<1.3	3258(18.33)	1054(27.44)	890(19.44)	759(15.17)	555(13.48)	
1.3-3.5	4728(35.27)	1310(41.51)	1278(37.77)	1250(34.53)	890(28.68)	
>3.5	4286(46.40)	731(31.05)	1057(42.79)	1266(50.30)	1232(57.84)	
Education n(%)						< 0.0001
Less than high school	2889(14.67)	1006(22.86)	829(16.81)	690(12.70)	364(8.25)	

Table 1 The baseline characteristics by quartiles of the OBS: NHANES 1999-2018

	High school	2729(22.94)	828(30.48)	752(26.69)	686(20.88)	463(15.61)	
	More than high school	6647(62.36)	1259(46.66)	1642(56.50)	1897(66.41)	1849(76.14)	
Sm	oke n(%)						< 0.0001
	Former	3273(26.54)	796(25.13)	887(26.25)	872(26.73)	718(27.76)	
	Never	7118(58.29)	1560(49.64)	1827(57.33)	1989(60.67)	1742(63.57)	
	Now	1875(15.14)	736(25.23)	510(16.42)	413(12.60)	216(8.67)	
Alc	ohol consumption n(%)						< 0.0001
	never	2126(14.10)	557(16.17)	592(16.07)	562(13.34)	415(11.37)	
	former	2809(18.98)	891(26.07)	769(19.39)	673(17.21)	476(14.85)	
	mild	5602(49.75)	1212(40.61)	1437(48.86)	1585(52.62)	1368(54.74)	
	moderate	1735(17.18)	435(17.16)	427(15.68)	455(16.82)	418(19.04)	
Tot	al energy, kcal/d	2027.49±10.98	1432.19±15.43	1836.37±18.08	2185.63±15.38	2512.74±19.56	< 0.0001
Hea	althy eating index(2015)	51.23(41.63,61.08)	43.06(35.33,51.45)	48.15(39.68,57.11)	51.98(42.81,61.12)	59.92(51.17,68.92)	< 0.0001
AL	T IU/L	20.00(16.00,27.00)	20.00(15.00,27.00)	20.00(16.00,26.00)	21.00(16.00,27.00)	20.00(16.00,27.00)	0.01
AS	Γ IU/L	22.00(19.00,26.00)	22.00(19.00,26.00)	22.00(19.00,26.00)	22.00(19.00,26.00)	23.00(20.00,27.00)	0.002
GG	T IU/L	64.00(52.00,78.00)	67.00(56.00,84.00)	65.00(54.00,79.00)	62.00(51.00,77.00)	61.00(50.00,74.00)	< 0.0001
ΤG	mg/dl	102.00(71.00,151.00)	111.00(76.00,162.00)	104.00(75.00,152.00)	102.00(72.00,154.00)	93.00(64.00,137.00)	< 0.0001
TC	mg/dl	192.00(166.00,221.00)	192.00(165.00,222.00)	194.00(166.00,221.00)	193.00(167.00,222.00)	191.00(165.00,217.00)	0.44
Scr	mg/dl	0.86(0.72,1.00)	0.86(0.73,1.01)	0.88(0.73,1.00)	0.84(0.72,1.00)	0.85(0.71,0.98)	< 0.001
BU	N mg/dl	5.30(4.40,6.30)	5.50(4.60,6.50)	5.40(4.50,6.40)	5.30(4.40,6.20)	5.10(4.30,6.00)	< 0.0001
CR	P mg/dl	0.18(0.07,0.42)	0.25(0.10,0.58)	0.19(0.08,0.45)	0.17(0.08,0.40)	0.13(0.06,0.31)	< 0.0001
HL	D mg/dl	52.00(43.00,64.00)	49.00(41.00,60.00)	52.00(44.00,62.00)	52.00(43.00,64.00)	56.00(45.00,67.00)	< 0.0001
LD	L mg/dl	113.00(91.00,138.00)	115.00(91.00,140.00)	114.00(92.00,140.00)	113.00(92.00,138.00)	111.00(89.00,134.00)	0.02
НО	MA IR	2.13(1.34,3.65)	2.41(1.50,4.11)	2.24(1.42,3.86)	2.10(1.33,3.62)	1.80(1.15,3.13)	< 0.0001
Glu	cose, mg/dL	5.50(5.11,5.98)	5.55(5.16,6.11)	5.55(5.16,6.05)	5.50(5.15,5.94)	5.39(5.05,5.83)	< 0.0001
Inst	ılin, U/mL	8.50(5.60,13.82)	9.59(6.29,15.58)	8.86(5.89,13.93)	8.41(5.56,13.87)	7.51(4.76,12.20)	< 0.0001

8128(69.92) 1057(8.41)	1952(66.49)	2041(66.17)	2224(71.56)	1001/74 44)	
1057(8.41)			2234(71.30)	1901(74.44)	
	277(9.00)	278(9.34)	292(7.70)	210(7.82)	
761(6.57)	174(5.82)	213(6.86)	199(7.04)	175(6.36)	
2326(15.11)	692(18.70)	693(17.63)	550(13.69)	391(11.38)	
					< 0.0001
10830(90.16)	2596(86.67)	2834(88.59)	2954(92.16)	2446(92.26)	
1442(9.84)	499(13.33)	391(11.41)	321(7.84)	231(7.74)	
					< 0.0001
6851(60.30)	1538(53.25)	1736(57.35)	1882(61.87)	1695(67.10)	
5418(39.67)	1555(46.75)	1488(42.65)	1393(38.13)	982(32.90)	
					< 0.0001
11771(96.70)	2904(94.83)	3097(96.54)	3167(97.26)	2603(97.96)	
491(3.24)	189(5.17)	126(3.46)	107(2.74)	69(2.04)	
					< 0.0001
8792(73.49)	2101(68.89)	2261(71.45)	2331(72.87)	2099(79.82)	
3480(26.51)	994(31.11)	964(28.55)	944(27.13)	578(20.18)	
					< 0.0001
11101(92.62)	2711(89.93)	2882(91.07)	3019(94.14)	2489(94.60)	
1171(7.38)	384(10.07)	343(8.93)	256(5.86)	188(5.40)	
	2326(15.11) 10830(90.16) 1442(9.84) 6851(60.30) 5418(39.67) 11771(96.70) 491(3.24) 8792(73.49) 3480(26.51) 11101(92.62) 1171(7.38)	101(0001) 111(0000) 2326(15.11) 692(18.70) 10830(90.16) 2596(86.67) 1442(9.84) 499(13.33) 6851(60.30) 1538(53.25) 5418(39.67) 1555(46.75) 11771(96.70) 2904(94.83) 491(3.24) 189(5.17) 8792(73.49) 2101(68.89) 3480(26.51) 994(31.11) 11101(92.62) 2711(89.93) 1171(7.38) 384(10.07)	$\begin{array}{ccccccc} 1110(000) & 111(0000) \\ 2326(15.11) & 692(18.70) & 693(17.63) \\ 10830(90.16) & 2596(86.67) & 2834(88.59) \\ 1442(9.84) & 499(13.33) & 391(11.41) \\ 6851(60.30) & 1538(53.25) & 1736(57.35) \\ 5418(39.67) & 1555(46.75) & 1488(42.65) \\ 11771(96.70) & 2904(94.83) & 3097(96.54) \\ 491(3.24) & 189(5.17) & 126(3.46) \\ 8792(73.49) & 2101(68.89) & 2261(71.45) \\ 943(1.11) & 964(28.55) \\ 11101(92.62) & 2711(89.93) & 2882(91.07) \\ 1171(7.38) & 384(10.07) & 343(8.93) \\ \end{array}$	$\begin{array}{c cccc} 11111111111111111111111111111111$	101(ub)10(ub)10(ub)10(ub)10(ub)2326(15.11)692(18.70)693(17.63)550(13.69)391(11.38)10830(90.16)2596(86.67)2834(88.59)2954(92.16)2446(92.26)1442(9.84)499(13.33)391(11.41)321(7.84)231(7.74)6851(60.30)1538(53.25)1736(57.35)1882(61.87)1695(67.10)5418(39.67)1555(46.75)1488(42.65)1393(38.13)982(32.90)11771(96.70)2904(94.83)3097(96.54)3167(97.26)2603(97.96)491(3.24)189(5.17)126(3.46)107(2.74)69(2.04)8792(73.49)2101(68.89)2261(71.45)2331(72.87)2099(79.82)3480(26.51)994(31.11)964(28.55)944(27.13)578(20.18)11101(92.62)2711(89.93)2882(91.07)3019(94.14)2489(94.60)1171(7.38)384(10.07)343(8.93)256(5.86)188(5.40)

ALT, alanine aminotransferase; AST, aspartate transaminase; GGT, g -glutamyl transferase; TG, triglycerides; TC, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HOMA IR, homeostasis model assessment insulin resistance; ; CRP, C-reactive protein; OBS, oxidative balance score; FIB-4, Fibrosis - 4 Index.

	Q1	Q2	Q3	Q4	p for trend
MASLD					
OBSQ					
crude model	ref	0.88(0.75,1.04)	0.82(0.69,0.99)	0.56(0.47,0.66)	< 0.0001
Model 1	ref	0.81(0.68,0.97)	0.81(0.67,0.98)	0.55(0.45,0.68)	< 0.001
Model 2	ref	0.66(0.55,0.79)	0.54(0.44,0.68)	0.31(0.24,0.40)	< 0.0001
Model 3	ref	0.77(0.62,0.97)	0.62(0.48,0.80)	0.37(0.27,0.51)	< 0.001
OBS.lifestyleQ					
crude model	ref	0.54(0.46,0.63)	0.47(0.39,0.57)	0.12(0.09,0.16)	< 0.0001
Model 1	ref	0.42(0.35,0.51)	0.35(0.28,0.44)	0.08(0.06,0.10)	< 0.0001
Model 2	ref	0.42(0.35,0.51)	0.35(0.28,0.44)	0.08(0.06,0.10)	< 0.0001
Model 3	ref	0.49(0.39,0.62)	0.51(0.39,0.68)	0.14(0.10,0.19)	< 0.0001
OBS.dietaryQ					
crude model	ref	0.92(0.77,1.09)	0.90(0.76,1.07)	0.74(0.62,0.87)	0.001
Model 1	ref	0.88(0.73,1.07)	0.94(0.78,1.14)	0.80(0.64,0.98)	0.07
Model 2	ref	0.75(0.61,0.92)	0.71(0.56,0.89)	0.52(0.40,0.68)	< 0.0001
Model 3	ref	0.74(0.57,0.95)	0.69(0.54,0.90)	0.48(0.36,0.66)	< 0.0001
MASLD-related fibrosis					
OBSQ					
crude model	ref	0.88(0.70,1.09)	0.56(0.45,0.69)	0.51(0.39,0.67)	< 0.0001
Model 1	ref	0.88(0.68,1.14)	0.66(0.52,0.84)	0.68(0.51,0.91)	0.002
Model 2	ref	0.87(0.67,1.13)	0.62(0.45,0.84)	0.60(0.42,0.87)	0.003
Model 3	ref	0.93(0.69, 1.25)	0.73(0.53, 1.02)	0.60(0.40, 0.91)	0.01
OBS.lifestyleQ					
crude model	ref	0.60(0.46,0.77)	0.52(0.39,0.70)	0.38(0.28,0.52)	< 0.0001
Model 1	ref	0.46(0.35,0.61)	0.47(0.35,0.64)	0.33(0.24,0.46)	< 0.0001
Model 2	ref	0.44(0.33,0.59)	0.46(0.33,0.63)	0.31(0.22,0.43)	< 0.0001
Model 3	ref	0.49(0.36, 0.67)	0.56(0.38, 0.84)	0.37(0.24, 0.56)	< 0.0001
OBS.dietaryQ					
crude model	ref	0.93(0.73,1.17)	0.62(0.49,0.77)	0.58(0.44,0.75)	< 0.0001
Model 1	ref	0.98(0.75,1.28)	0.76(0.60,0.97)	0.82(0.62,1.07)	0.04
Model 2	ref	0.98(0.74,1.29)	0.76(0.57,1.01)	0.78(0.56,1.09)	0.07
Model 3	ref	1.01(0.73, 1.40)	0.83(0.61, 1.14)	0.72(0.48, 1.08)	0.08

Table 2 The associations between different OBS and NAFLD and NAFLD-related fibrosis

crudel model: Unadjusted model.

model 1: Adjusted for age, sex, race, marital status, PIR, education, smoke, alcohol.user

model 2: Additionally adjusted for SII, energy_kcal

model 3: Additionally adjusted for ALT, AST, GGT, Scr, BUN, Total energy, TC, Glucose, TG, DM, CVD, Hypertension, Stroke.

Test for trend based on the variable containing a median value for each quartile.

Subgroup	MASLD	OR(95%CI)	P interaction	MASLD related fibrosis	OR(95%CI)	P interaction
Sex			0.15			0.87
Male	H -	0.96(0.94,0.98)			0.96(0.93,0.99)	
Female	H=	0.93(0.91,0.95)			0.96(0.94,0.99)	
Age			0.76			0.76
<60 yr	H -	0.95(0.93,0.97)			0.97(0.92,1.03)	
≥60 yr	H=H	0.94(0.93.0.96)			0.98(0.96,1.00)	
marital			0.39			0.43
Having a partner	H=+	0.94(0.92,0.96)			0.95(0.93,0.98)	
No partner	→	0.95(0.93,0.98)			0.97(0.94,1.00)	
Unmarried	⊢	0.95(0.90,0.99)		L	1.01(0.92,1.11)	
PIR3			0.86			0.94
<1.3	⊢ ■-1	0.94(0.91,0.96)		F=-1	0.97(0.94.1.01)	
1.3-3.5	H=	0.96(0.94,0.99)			0.96(0.93.0.99)	
>3.5	H=-1	0.95(0.93.0.97)			0.96(0.92.1.00)	
edu			0.95			0.87
Less than high school	⊢ ∎- 1	0.98(0.95.1.01)			0.96(0.92,1.00)	
high school		0.95(0.92,0.98)			0.94(0.91,0.98)	
More than high school	Her-H	0.93(0.92,0.95)			0.97(0.94,1.00)	
race			0.77			0.71
Mexican American	⊢ ∎−−−1	0.95(0.92,0.99)			0.96(0.90,1.02)	
Other Hispanic		0.89(0.84,0.93)		F	0.89(0.82,0.96)	
Non-Hispanic Black		0.95(0.92,0.98)			0.95(0.91,0.99)	
Non-Hispanic White	H-#H	0.95(0.93,0.96)			0.97(0.94,1.00)	
Other Race - Including Multi-Racial	⊢ −−−1	0.94(0.89,0.99)			0.83(0.75,0.90)	
	0.7 0.8 0.9 1	1.1	0.	7 0.8 0.9 1.0 1.1	1.2	
	OR(95%CI)			OR(95%CI)		

Subgroup analysis of associations between OBS and odds of MASLD and MASLD related fibrosis



Analysis of Restricted Cubic Spline Regression. Adjusted restricted cubic spline models adjusted for age, sex, race, marital status, HEI,PIR, education, smoke, alcohol.user,SII, total energy intake,ALT, AST, GGT, creatinine, BUN, Total energy, TC, Glucose, TG,DM, CVD, Hypertension, Stroke.